{
    "clinical_study": {
        "@rank": "3242", 
        "acronym": "YH16410 DDI", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2."
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2."
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Experimental", 
                "description": "This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2."
            }, 
            {
                "arm_group_label": "4", 
                "arm_group_type": "Experimental", 
                "description": "This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2."
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial is designed to compare the pharmacokinetic characteristics of\n      combination and separate administration of Crestor(Rosuvastatin) and Micardis(Telmisartan).\n      Also investigate drug interaction between separate and combination administration.\n\n      Total number of subjects is 48. 4 group(12 for 1 group), 2 period, consecutive 6 day\n      administration, 16 days washout after 6th day of administration.\n\n      The subjects of Part 1 take Crestor alone and Crestor+Micardis combination by a cross-over\n      design during 2 each period.\n\n      The other subjects of Part 2 take Micardis alone and Crestor+Micardis combination by a\n      cross-over design during 2 each period."
        }, 
        "brief_title": "A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male and female aged 20 to 50 with a body mass index(BMI) between 19 and 27\n             kg/m2\n\n          2. Acceptable medical history, physical examination, laboratory tests and EKG, during\n             screening\n\n          3. Provision of signed written informed consent \u202220~50 yrs old, healthy Korean Subjects\n\n        Exclusion Criteria:\n\n        1.History of and clinically significant disease 2.Sitting blood pressure meeting the\n        following criteria at screening: 150 \u2264 systolic blood pressure \u226490  (mmHg) and 95 \u2264\n        diastolic blood pressure \u2264 50 (mmHg) amd 100 \u2264 Heart rate \u2264 40 3. A history of drug abuse\n        or the presence of positive reactions to drugs that have abuse potential in urine\n        screenings for drugs.\n\n        4. Administration of other investigational products within 90 days prior to the first\n        dosing.\n\n        5. Administration of herbal medicine within 30 days or administration of ethical drugs\n        within 14 days or administration of over-the-counter (OTC) drugs within 7 days prior to\n        the first dosing of the investigational product (if the investigator (study doctor)\n        determines that the person meets other criteria appropriately, the relevant person may\n        participate in the study).\n\n        6.Have AST(SGOT) or/and ALT(SGPT) > 3 times of normal upper limit at the time of screening\n        7. Volunteers considered not eligible for the clinical trial by the investigator (study\n        doctor) due to reasons including laboratory test results, ECGs, or vital signs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992601", 
            "org_study_id": "YH16410-101"
        }, 
        "intervention": {
            "arm_group_label": [
                "1", 
                "2", 
                "3", 
                "4"
            ], 
            "description": "For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.\nFor separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.", 
            "intervention_name": "Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Telmisartan", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug interaction", 
            "Rosuvastatin", 
            "Telmisartan", 
            "Pharmacokinetic", 
            "(Pharmacokinetics and Drug Interaction)"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital, Yonsei University"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC \u03c4,ss of Rosuvastatin and Telmisartan", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "Cmax,ss of Rosuvastatin and Telmisartan", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992601"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC last,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "AUC inf,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "Tmax,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "t1/2 of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "Cmin,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan", 
                "measure": "Cmin", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "AUC\u03c4,ss of N-desmetyl Rosuvastatin", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }, 
            {
                "description": "Cmax,ss of N-desmetyl Rosuvastatin", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "72hr"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}